Urticaria
📧 Sign up to get email alerts when something new happens for Urticaria.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-07-30FDA Approved: FEXOFENADINE HYDROCHLORIDE — Original Application (DR REDDYS)
FDA approval information for the original application of fexofenadine hydrochloride (generic antihistamine) by Dr. Reddy's.
-
EMA approval · 2026-07-10EMA Authorised: Desloratadine Actavis (desloratadine) — Actavis Group PTC ehf
Authorised Desloratadine Actavis (desloratadine) for allergic rhinitis and urticaria in the EU.
-
EMA approval · 2026-07-10EMA Authorised: Desloratadine ratiopharm (desloratadine) — Ratiopharm GmbH
Authorised desloratadine product from Ratiopharm (desloratadine) for allergic rhinitis and urticaria indications in the EU.
-
EMA approval · 2026-06-08EMA Authorised: Xolair (omalizumab) — Novartis Europharm Limited
EMA has authorised Xolair (omalizumab) for indications including asthma, urticaria, and rhinitis, under the MAH Novartis Europharm Limited.
-
EMA approval · 2026-06-05EMA Authorised: Dasselta (desloratadine) — Krka, d.d., Novo mesto
Dasselta (desloratadine) by Krka has been authorised for allergic rhinitis (perennial and seasonal) and urticaria in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Screening Protocol for Genetic Diseases of Allergic Inflammation
Completed clinical trial update describing a screening protocol for genetic diseases involved in allergic inflammation.
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
This real-world study evaluates omalizumab treatment patterns in Chinese patients with chronic urticaria. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of ARS-1 with intranasal epinephrine in subjects with frequent urticaria flares has compl…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of remibrutinib (LOU064) in chronic urticaria, including chronic spontaneous …
-
FDA approval · 2026-03-24FDA Approved: ZYRTEC — Supplemental Application (Kenvue Brands LLC)
FDA approved a supplemental application for ZYRTEC (cetirizine hydrochloride) filed by Kenvue Brands LLC. This action confirms regulatory ap…
-
EMA approval · 2026-03-19EMA Authorised: Neoclarityn (desloratadine) — Organon N.V.
The EMA authorised Neoclarityn (desloratadine) by Organon N.V. for allergic rhinitis (perennial and seasonal) and urticaria.
-
EMA approval · 2026-03-19EMA Authorised: Aerius (desloratadine) — Organon N.V.
The European Medicines Agency has authorised Aerius (desloratadine), a non-sedating antihistamine for allergic rhinitis (perennial and seaso…
-
CLINICAL_TRIALS other · 2026-03-18Clinical Trial Update: A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology [NA]
This is a randomized controlled trial assessing ePROM-guided flexible scheduling in dermatology, targeting eczema (atopic dermatitis), urtic…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria [Phase 2]
Phase 2 clinical trial update reporting efficacy and safety data for povorcitinib in adults with chronic spontaneous urticaria; results comp…
-
FDA approval · 2026-03-05FDA Approved: CHILDRENS XYZAL ALLERGY — Supplemental Application (Chattem, Inc.)
The FDA approved a supplemental application for Children's XYZAL Allergy (levocetirizine dihydrochloride) from Chattem, Inc., signaling a la…
-
EMA approval · 2026-03-02EMA Authorised: Azomyr (desloratadine) — Organon N.V.
The European Medicines Agency authorised Azomyr, a desloratadine-containing medicine by Organon N.V., for allergic rhinitis (seasonal and pe…
-
FDA approval · 2026-02-25FDA Approved: CETIRIZINE HYDROCHLORIDE — Original Application (Advagen Pharma Ltd.,)
FDA approved cetirizine hydrochloride via Original Application (ANDA) for Advagen Pharma Ltd.
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
The clinical trial evaluating an AI diagnostic tool for primary care doctors assessing skin conditions has been completed. The study evaluat…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials [Phase 2]
Phase 2 open-label extension study to evaluate long-term safety and clinical activity of briquilimab in participants from Jasper Therapeutic…
-
FDA approval · 2026-01-30FDA Approved: CETIRIZINE HCL — Supplemental Application (AMERISOURCE BERGEN)
The FDA approved a supplemental application for cetirizine hydrochloride, submitted by Amerisource Bergen.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Deep Phenotyping of CIndU
A clinical trial update from the Centre for Human Drug Research (Netherlands) recruiting participants to deeply phenotype chronic inducible …
-
FDA approval · 2025-12-24FDA Approved: CHILDRENS ZYRTEC — Supplemental Application (Kenvue Brands LLC)
FDA approves a supplemental application for Children's ZYRTEC (cetirizine hydrochloride) to update labeling/indications submitted by Kenvue …
-
FDA approval · 2025-11-25FDA Approved: CETIRIZINE HYDROCHLORIDE — Supplemental Application (BAJAJ MEDICAL, LLC)
FDA approved a supplemental application for cetirizine hydrochloride from Bajaj Medical, LLC, authorizing continued marketing of the generic…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria [NA]
This study protocol compares standard-dose and high-dose cetirizine for acute urticaria and is not yet recruiting.
-
EMA approval · 2025-11-18EMA Authorised: Omlyclo (omalizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorised Omlyclo (omalizumab) by Celltrion Healthcare Hungary Kft. for asthma and urticaria.